Valmet Reports 25% Organic Order Growth, Q3 Comparable EBITA of €169 Million
Valmet reaffirmed 2026 guidance, expecting sales to remain flat versus 2025 and comparable EBITA to be flat or higher than 2025’s €620 million. Its strategic review of a potential separation of two business units is ongoing, with about €10 million in related costs expected in Q4.
Valmet Oyj announced its third-quarter 2026 results, highlighting a 25% organic growth in order intake and a rise in comparable EBITA to €169 million. The company reaffirmed its financial guidance for 2026, maintaining expectations for sales to remain flat compared to 2025 and EBITA to be flat or higher than the previous year's €620 million. Additionally, the company noted that its strategic review regarding a potential separation of two business units is ongoing, with approximately €10 million in related costs expected in the fourth quarter.
The results were supported by strong capital orders in the biomaterials sector, particularly in China and the APAC region, which are expected to expand the company's installed base and future service revenue.